Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)-Reference-Cited by-同舟云学术

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)

Published:2022-01-20 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Aschmoneit Nadine¹^ORCID,Kocher Katharina¹^ORCID,Siegemund Martin¹,Lutz Martina S.¹,Kühl Lennart¹^ORCID,Seifert Oliver¹²^ORCID,Kontermann Roland E.¹²^ORCID

Affiliation:

1. Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany

2. Stuttgart Research Center Systems Biology (SRCSB), University of Stuttgart, Stuttgart, Germany

Funder

no funding associated

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2028961

Reference48 articles.

1. T-cell agonists in cancer immunotherapy

2. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters

3. Molecular mechanisms of T cell co-stimulation and co-inhibition

4. Costimulation of T cells by OX40, 4-1BB, and CD27

5. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of costimulatory molecule signatures for evaluating prognostic risk in non-small cell lung cancer;Heliyon;2024-09

2. Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes;Cells;2023-06-09

3. Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives;Frontiers in Immunology;2023-04-25

4. Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy;BioDrugs;2022-12-26